肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：DC疫苗可以增强免疫反应及诱导HER2阳性DCIS病情缓解

2017-07-01 MedSci MedSci原创

DC疫苗HER2阳性乳腺癌
关注

HER-2抗原冲击DC1制备的疫苗可以刺激HER-2特异性T细胞反应。CLIN CANCER RES近期发表了一篇文章，评估该疫苗的安全性以及通过不同途径给药的免疫反应及临床效果

HER-2抗原冲击DC1制备的疫苗可以刺激HER-2特异性T细胞反应。CLIN CANCER RES近期发表了一篇文章，评估该疫苗的安全性以及通过不同途径给药的免疫反应及临床效果。该研究共纳入54例HER2阳性患者（42例单纯导管原位癌（DCIS），12例早期浸润性乳腺癌（IBC））。患者随机分到3个给药方式组，其中病灶内给药（IL）19例，淋巴结内给药（IN）19例，病灶及淋巴结联合给药（ILN）16例。作者评估了外周血及前哨淋巴结的免疫反应，并研究了切除肿瘤标本的病理学反应。研究结果发现，通过3中注射方式给药的疫苗耐受性均良好。不同给药途径免疫反应率无明显差别（IL84.2%。IN89.5%，ILN66.7，P=0.30）。与IBC患者相比，DCIS患者的病理完全缓解（pCR）率更高（28.6% vs 8.3%）。达到pCR的DCIS患者与未达到pCR的DCIS患者外周血抗HER2免疫反应相似。所有达到pCR的患者在前哨淋巴结中均出现抗HER2 CD4免疫反应。文章最后认为，抗HER2 DC1疫苗是一项安全的免疫原性治疗方式，可以诱导HER2阳性患者的肿瘤特异性T细胞反应。不同给药

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1661882, encodeId=e11a166188208, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Wed Jun 06 10:21:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993598, encodeId=5eb61993598c2, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jul 08 20:21:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765015, encodeId=2fab1e6501507, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 22 03:21:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280162, encodeId=fcf012801628f, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308491, encodeId=44181308491d0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218023, encodeId=a0af2180237f, content=好文，值得点赞！认真学习了，把经验应用于实践，为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:26 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217577, encodeId=87bd21e57742, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:29:47 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2018-06-06 ms691033630344116

    #DCI#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1661882, encodeId=e11a166188208, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Wed Jun 06 10:21:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993598, encodeId=5eb61993598c2, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jul 08 20:21:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765015, encodeId=2fab1e6501507, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 22 03:21:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280162, encodeId=fcf012801628f, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308491, encodeId=44181308491d0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218023, encodeId=a0af2180237f, content=好文，值得点赞！认真学习了，把经验应用于实践，为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:26 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217577, encodeId=87bd21e57742, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:29:47 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-08 12498ebem19暂无昵称

    #CIS#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1661882, encodeId=e11a166188208, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Wed Jun 06 10:21:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993598, encodeId=5eb61993598c2, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jul 08 20:21:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765015, encodeId=2fab1e6501507, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 22 03:21:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280162, encodeId=fcf012801628f, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308491, encodeId=44181308491d0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218023, encodeId=a0af2180237f, content=好文，值得点赞！认真学习了，把经验应用于实践，为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:26 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217577, encodeId=87bd21e57742, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:29:47 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-08-22 柳叶一刀

    #病情#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1661882, encodeId=e11a166188208, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Wed Jun 06 10:21:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993598, encodeId=5eb61993598c2, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jul 08 20:21:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765015, encodeId=2fab1e6501507, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 22 03:21:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280162, encodeId=fcf012801628f, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308491, encodeId=44181308491d0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218023, encodeId=a0af2180237f, content=好文，值得点赞！认真学习了，把经验应用于实践，为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:26 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217577, encodeId=87bd21e57742, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:29:47 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-03 cnxcy

    #免疫反应#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1661882, encodeId=e11a166188208, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Wed Jun 06 10:21:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993598, encodeId=5eb61993598c2, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jul 08 20:21:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765015, encodeId=2fab1e6501507, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 22 03:21:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280162, encodeId=fcf012801628f, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308491, encodeId=44181308491d0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218023, encodeId=a0af2180237f, content=好文，值得点赞！认真学习了，把经验应用于实践，为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:26 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217577, encodeId=87bd21e57742, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:29:47 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-03 闆锋旦

    #HER2阳性#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1661882, encodeId=e11a166188208, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Wed Jun 06 10:21:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993598, encodeId=5eb61993598c2, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jul 08 20:21:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765015, encodeId=2fab1e6501507, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 22 03:21:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280162, encodeId=fcf012801628f, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308491, encodeId=44181308491d0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218023, encodeId=a0af2180237f, content=好文，值得点赞！认真学习了，把经验应用于实践，为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:26 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217577, encodeId=87bd21e57742, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:29:47 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-03 ylzr123

    好文，值得点赞！认真学习了，把经验应用于实践，为患者解除病痛。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1661882, encodeId=e11a166188208, content=<a href='/topic/show?id=85485e479f' target=_blank style='color:#2F92EE;'>#DCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5747, encryptionId=85485e479f, topicName=DCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=100e25353151, createdName=ms691033630344116, createdTime=Wed Jun 06 10:21:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993598, encodeId=5eb61993598c2, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jul 08 20:21:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765015, encodeId=2fab1e6501507, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 22 03:21:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280162, encodeId=fcf012801628f, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308491, encodeId=44181308491d0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Jul 03 11:21:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218023, encodeId=a0af2180237f, content=好文，值得点赞！认真学习了，把经验应用于实践，为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:26 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217577, encodeId=87bd21e57742, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:29:47 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-02 184****9840

    学习了谢谢分享

    0